期刊文献+

利妥昔单克隆抗体联合氟达拉滨及环磷酰胺治疗慢性淋巴细胞白血病 被引量:8

Treatment of Chronic Lymphocytic Leukemia with Regimen of Fludarabine,Cyclophosphamide and Rituximab
下载PDF
导出
摘要 为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。FCR方案包括氟达拉滨25mg/m2第2-4天静脉滴注,环磷酰胺250mg/m2第2-4天静脉滴注,利妥昔单克隆抗体375mg/m2第1天静脉滴注,每28天1个疗程。采用多参数流式细胞术检测微小残留病灶(MRD)。结果表明:3例达完全缓解,2例部分缓解;5例中2例MRD检测为阴性。FCR方案的毒副作用主要表现为骨髓抑制和胃肠道反应。结论:FCR方案对CLL的治疗有确切疗效,值得进一步推广使用。 In order to evaluate the effecicney of rituximab combined with fludarabine, cyclophosphamide and rituximab (FCR) regimen for chronic lymphocytic leukemia (CLL). Five patients with CLL were treated with FCR regimen for 2 -6 courses. FCR regimen included fludarabine 25 mg/m^2 via intraveneous drip at day 2 -4, cyclophosphamide 250 mg/m^2 via intraveneous drip at day 2 -4 and rituximab 375 mg/m^2 via intraveneous drip at day 1. Courses were repeated every 4 weeks. Minimal residu disease (MRD) was determined by multiparametic flow cytometry. The results showed that three patiens achieved complete remission, 2 patients achieved partial remission. MRD was negative in two patiens. In conclusion, FCR is an effective therapeutic regimen for treating CLL patients and is worth to be used in clinic.
出处 《中国实验血液学杂志》 CAS CSCD 2008年第4期938-942,共5页 Journal of Experimental Hematology
基金 江苏省医学领军人才基金资助项目 江苏省医学重点人才基金资助项目 编号RC2007042 江苏省自然基金基助项目 编号BK2007249 江苏省社会发展计划基金资助项目 编号BS2007075
关键词 慢性淋巴细胞白血病 FCR方案 利妥昔单克隆抗体 氟达拉滨 环磷酰胺 chronic lymphocytic leukemia FCR regimen rituximab fludarabine cyclophosphamide
  • 相关文献

参考文献12

  • 1Lin TS. What is the optimal initial treatment for chronic lymphocytic leukemia? Oncology ( Williston Park), 2007 ;21 : 1641 - 1649
  • 2Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev, 2007 ; 33:710 -728
  • 3Pepper C, Lowe H, Fegan C, et al. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136( NSC 694501 ) in chronic lymphocytic leukaemia cells. Br J Cancer, 2007 ;97:253 -259
  • 4Dalle S, Dumontet C. Rituximab: mechanism of action and resistance. Bull Cancer, 2007 ;94:198 -202
  • 5Hil.lmen P. Advancing therapy for chronic lymphocytic leukemia - the role of rituximab. Semin Oncol, 2004;31 ( Suppl 2) ,22 -26
  • 6Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 2005 ;4079 -4088
  • 7Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol, 2005;23: 4070 -4078
  • 8Sayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Praet Res Clin Haematol, 2007 ;20:499 -512
  • 9李丽,徐卫,李建勇.慢性淋巴细胞白血病预后因素研究进展[J].中华内科杂志,2006,45(9):781-783. 被引量:17
  • 10李丽,徐卫,仇海荣,程月新,张苏江,李建勇.探针D13S319和D13S25检测慢性淋巴细胞白血病13q14缺失[J].中国实验血液学杂志,2007,15(2):229-232. 被引量:8

二级参考文献45

  • 1张颜明.荧光原位杂交技术检测外周T细胞淋巴瘤的染色体畸变[J].中华肿瘤杂志,1995,17(3):187-190. 被引量:5
  • 2徐卫,李建勇,潘金兰,仇海荣,沈云锋,肖冰,陈丽娟,吴亚芳,盛瑞兰,薛永权.慢性淋巴细胞白血病的分子遗传学特点[J].中华肿瘤杂志,2006,28(5):349-352. 被引量:13
  • 3李丽,徐卫,李建勇.慢性淋巴细胞白血病预后因素研究进展[J].中华内科杂志,2006,45(9):781-783. 被引量:17
  • 4Glassman AB,Hayes KJ.The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia.Cancer Genet Cytogenet,2005,158:88-91.
  • 5International Workshop on Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia:recommendations for diagnosis,staging,and response criteria.Ann Intern Med,1989,110:236-238.
  • 6Stilgenbauer S,Dohner K,Bentz M,et al.Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia.Ann Hematol,1998,76:101-110.
  • 7Dewald GW,Brockman SR,Paternoster SF,et al.Chromosome anomalies detected by interphase fluorescence in situ hybridization:correlation with significant biological features of B-cell chronic lymphocytic leukaemia.Br J Haematol,2003,121:287-295.
  • 8Aoun P,Blair HE,Smith LM,et al.Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.Leuk Lymphoma,2004,45:1595-1603.
  • 9Thornton PD,Gruszka-Westwood AM,Hamoudi RA,et al.Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.Hematol J,2004,5:47-54.
  • 10Aoun P,Blair HE,smith LM,et al.Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.Leuk Lymphoma,2004,45:1595-1603.

共引文献33

同被引文献45

  • 1王新禹,梁前进.环磷酰胺的毒副作用机制及应对措施[J].药学进展,2006,30(10):452-456. 被引量:40
  • 2郑文娟,陈丽娟,吴雨洁,李丽,徐卫,李建勇.应用多重PCR技术检测慢性淋巴细胞白血病IgVH基因突变[J].中国实验血液学杂志,2006,14(6):1101-1104. 被引量:8
  • 3张曦,周立宇,李晓,徐黎,宋陆茜,应韶旭,浦权.氟达拉滨治疗慢性淋巴细胞白血病15例临床观察[J].中国医师进修杂志(内科版),2007,30(7):56-57. 被引量:3
  • 4EichhorstB, Hallek M. Revision of the guidelines for diagnosis and therapty of chronic lymphocitic leukmia (CLL). Research Clinical Haematology ,2007,20( 3 ) :469-477.
  • 5Rossi D, Gaidano G. Richter syndrome: molecular insights and clin- ical perspectives. Hematol Oncol, 2009 ;27 ( 1 ) : 1 - 10.
  • 6Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase Ⅰ-Ⅱ study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol, 2008 ;26 (2) : 196 - 203.
  • 7Tsimberidou AM, Keating MJ. Richter syndrome: biology, inci- dence, and therapeutic strategies. Cancer, 2005 ; 103 (2) :216 - 228.
  • 8Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin trans- formation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer, 2006 ; 107 ( 6 ) : 1294 - 1302.
  • 9Yamazaki ML, Lum CA, Izumi AK. Primary cutaneous Richter syn-drome: prognostic implications and review of the literature. J Am Acad Dermatol, 2009 ;60( 1 ) : 157 - 161.
  • 10Robak E, Gora-Tybor J, Kordek R, et al. Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from pri- mary B-cell chronic lymphocytic leukaemia. Br J Dermatol, 2005; 153(4) :833 -837.

引证文献8

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部